Select your investor profile:
This content is only for the selected type of investor.
Individual investor?
Trip notes: opportunities and challenges in Chinese healthcare
Anna Mulholland goes on a fact-finding mission to understand the investment opportunities in the Chinese and Korean healthcare industries
Written by
A glimpse of traditional Chinese medicine (TCM)
During a recent tour of a modern Beijing hospital, I asked to see their traditional Chinese medicine department. Like many Westerners I’m both curious and sceptical about these exotic remedies.
Jokingly, I asked whether they might have a cure for jetlag. But they took me seriously and gave me a consultation on the spot and then two of vials of a prescribed mixture. What surprised me most was how my guide, the hospital’s millennial Investor Relations Officer, reacted – astonished disbelief that I might really want to give the cure a try. Nor was he unusual. Chinese millennials generally seem surprised that Westerners might take an interest in their traditional treatments.
I suppose at the roots of that reaction are the concerted efforts China is making in adopting Western-style medicine. The country’s vast and increasingly wealthy, but generally under-provided population is creating a huge market for modern treatments.
I visited some 30 companies involved along the full healthcare chain during my trip to Shanghai, Beijing, Hong Kong and Seoul to find out more.
People queuing at a hospital in China
Photo taken by Anna Mulholland, Senior Investment Manager, on her latest trip to China
Chinese healthcare - Opportunities
China wants, and rather desperately needs, a sustainable and self-sufficient healthcare system. The process of attaining this will almost certainly place it as a leader on the global healthcare stage. The urgency to make both of these things happen is palpable within the ‘traditional’ pharma companies and even more so at the Biologics or Biopharma companies.
The pool of patients is immense and their potential clinical needs vast. Pick any disease or condition, and the numbers are staggering. Cancer has been the leading cause of death in China since 2010. Last year four million people were diagnosed with cancer and over two million people died from it. Lung cancer is the most prevalent, followed by stomach and liver cancer, for which China accounts for more than half of cases globally. 100 million people in China have diabetes. 200 million people suffer from high blood pressure. There are over two million new stroke patients each year.
Other, less obvious threats are waiting in the wings too: in a system under pressure from lack of doctors per patient, time to diagnose is short. Over-prescription is common as is drug resistance. One Biotech CFO pointed out that many superbugs will develop in China and the global world we live in means its likely they will spread quickly.
To deliver the necessary medicine and services requires getting over two major hurdles: Accessibility and Affordability. The government’s way of surmounting those hurdles is accelerated new drug approvals and improved cost reimbursements. There is a keen focus on rewarding successful innovation in this way.
Accessibility: Everyone's a winner
On the accessibility challenge, the largest unmet clinical needs are in oncology, auto-immune diseases, and cardiovascular treatments. Other interesting areas include ophthalmology and mental health, where diagnosis rates remain considerably above global averages. Oncology is probably the biggest market opportunity for healthcare companies. Chinese patients have limited access to more advanced cancer treatments – only 29 of 105 targeted therapies approved in the US are currently available in China. Last year, around 60 per cent of cancer treatment in China was via older-generation chemotherapy, compared to 10 per cent in the US.
Competition to take market share in the new and innovative drug space is unsurprisingly fierce but the size of the prize is so large that there should really be no losers.Last year, around 60% of cancer treatment in China was via older-generation chemotherapy, compared with 10% in the US.
Affordability: the pricing pressure is here to stay
China has a single-payer healthcare system – in theory this means the government pays for everything. However, as with the funding of healthcare systems in large economies in the West, the funding needs from government coffers is increasing whilst they themselves are shrinking. As such, patient cost-sharing remains a necessary reality, in some cases for up to 90% of the total treatment cost.
At the heart of price control is the government’s National Reimbursement Drug List. There are 2535 products on the list. When a drug enters the list, its price or level of reimbursement is negotiated via tender. A cut of 50 per cent to the pre-list price is common, especially for branded and innovative drugs. The NRDL has been reviewed every 5 to 7 years in the past but it is likely to be reviewed much more frequently to accommodate the inclusion of more innovative drugs. In fact, at the last list update in 2017, the government put 45 products onto a ‘to be negotiated’ list, half of which were oncology therapies. The drugs which avoid the tender process are exclusive or first to market drugs in therapeutic areas with urgent clinical needs.
Further articles from the emerging Equities team
Trip notes: Diamonds in the Rough
Gita Ramakrishnan, Senior Investment Manager
August 2018
Trip notes: Chasing Chinese Unicorns
James Kenney, Senior Investment Manager
August 2018
Important legal information
This marketing document is issued by Pictet Asset Management. It is neither directed to, nor intended for distribution or use by any person or entity who is a citizen or resident of, or domiciled or located in, any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Only the latest version of the fund’s prospectus, the KIID (Key Investor Information Document), regulations, annual and semi-annual reports may be relied upon as the basis for investment decisions. These documents are available on assetmanagement.pictet.
This document is used for informational purposes only and does not constitute, on Pictet Asset Management part, an offer to buy or sell solicitation or investment advice. It has been established on the basis of data, projections, forecasts, anticipations and hypothesis which are subjective. Its analysis and conclusions are the expression of an opinion, based on available data at a specific date. The effective evolution of the economic variables and values of the financial markets could be significantly different from the indications communicated in this document.
Information, opinions and estimates contained in this document reflect a judgment at the original date of publication and are subject to change without notice. Pictet Asset Management has not taken any steps to ensure that the securities referred to in this document are suitable for any particular investor and this document is not to be relied upon in substitution for the exercise of independent judgment. Tax treatment depends on the individual circumstances of each investor and may be subject to change in the future. Before making any investment decision, investors are recommended to ascertain if this investment is suitable for them in light of their financial knowledge and experience, investment goals and financial situation, or to obtain specific advice from an industry professional.
The value and income of any of the securities or financial instruments mentioned in this document may fall as well as rise and, as a consequence, investors may receive back less than originally invested. Risk factors are listed in the fund’s prospectus and are not intended to be reproduced in full in this document.
Past performance is not a guarantee or a reliable indicator of future performance. Performance data does not include the commissions and fees charged at the time of subscribing for or redeeming shares. This marketing material is not intended to be a substitute for the fund’s full documentation or for any information which investors should obtain from their financial intermediaries acting in relation to their investment in the fund or funds mentioned in this document.
EU countries: the relevant entity is Pictet Asset Management (Europe) S.A., 15, avenue J. F. Kennedy, L-1855 Luxembourg
Switzerland: the relevant entity is Pictet Asset Management SA , 60 Route des Acacias – 1211 Geneva 73
Hong Kong: this material has not been reviewed by the Securities and Futures Commission or any other regulatory authority. The issuer of this material is Pictet Asset Management (Hong Kong) Limited.
Singapore: this material is issued by Pictet Asset Management (Singapore) Pte Ltd. This material is intended only for institutional and accredited investors and it has not been reviewed by the Monetary Authority of Singapore.
For Australian investors, Pictet Asset Management Limited (ARBN 121 228 957) is exempt from the requirement to hold an Australian financial services license, under the Corporations Act 2001.
For US investors, Shares sold in the United States or to US Persons will only be sold in private placements to accredited investors pursuant to exemptions from SEC registration under the Section 4(2) and Regulation D private placement exemptions under the 1933 Act and qualified clients as defined under the 1940 Act. The Shares of the Pictet funds have not been registered under the 1933 Act and may not, except in transactions which do not violate United States securities laws, be directly or indirectly offered or sold in the United States or to any US Person. The Management Fund Companies of the Pictet Group will not be registered under the 1940 Act.
For US investors, Shares sold in the United States or to US Persons will only be sold in private placements to accredited investors pursuant to exemptions from SEC registration under the Section 4(2) and Regulation D private placement exemptions under the 1933 Act and qualified clients as defined under the 1940 Act. The Shares of the Pictet funds have not been registered under the 1933 Act and may not, except in transactions which do not violate United States securities laws, be directly or indirectly offered or sold in the United States or to any US Person. The Management Fund Companies of the Pictet Group will not be registered under the 1940 Act.
Pictet Asset Management Inc. (Pictet AM Inc) is responsible for effecting solicitation in North America to promote the portfolio management services of Pictet Asset Management Limited (Pictet AM Ltd) and Pictet Asset Management SA (Pictet AM SA).
In Canada Pictet AM Inc. is registered as Portfolio Manager authorised to conduct marketing activities on behalf of Pictet AM Ltd and Pictet AM SA. In the USA, Pictet AM Inc. is registered as an SEC Investment Adviser and its activities are conducted in full compliance with the SEC rules applicable to the marketing of affiliate entities as prescribed in the Adviser Act of 1940 ref. 17CFR275.206(4)-3.